June 24, 2022
The U.S. Food and Drug Administration issued a draft guidance for industry titled Considerations for Rescinding Breakthrough Therapy Designation. This draft guidance explains how FDA may consider whether to rescind a breakthrough therapy designation (BTD) during its evaluation of a drug development program.
FDA’s BTD program facilitates and expedites the development of drugs that receive BTD designation. The agency has authority to grant BTD only to drugs that meet the legal criteria, and periodically assesses whether designated products continue to meet the criteria for BTD. The information supporting FDA’s granting of BTD for a particular drug or biologics may change over time. Some drugs or biologics that appear promising in early development, for example, may not be shown to be safe or effective in later trials. If the BTD designation is no longer supported by subsequent data, FDA may rescind the designation.
For information on the draft guidance and how to comment, please see the Federal Register Notice.
Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.
We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.
Interested in gaining an industry edge? Let us help you stay up to date.
Gain an Industry Edge With Expertise From ProPharma Group
Get the latest insights and top tips from our experts, delivered right to your inbox.
Have a complex challenge?